Most Recent Additions*


Analysis of Brain Structural Connectivity Networks and White Matter Integrity in Patients With Mild Cognitive Impairment.
Maurizio Bergamino, Simona Schiavi, Alessandro Daducci, Ryan R Walsh, and Ashley M Stokes


Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion-Weighted MRI Metrics in Cognitive Decline.
Maurizio Bergamino, Anna Burke, Leslie C Baxter, Richard J Caselli, Marwan N Sabbagh, Joshua S Talboom, Matthew J Huentelman, and Ashley M Stokes


Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease.
A Parsian, B Racette, Z H Zhang, S Chakraverty, M Rundle, A Goate, and J S Perlmutter


Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset.
Abbas Parsian, Brad Racette, L Jane Goldsmith, and Joel S Perlmutter


Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups.
A Parsian, B Racette, Z H Zhang, M Rundle, and J S Perlmutter


Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.
Rashmi Sinha, Brad Racette, Joel S Perlmutter, and Abbas Parsian


Relative risk of spread of symptoms among the focal onset primary dystonias.
Elliott M Weiss, Tamara Hershey, Morvarid Karimi, Brad Racette, Samer D Tabbal, Jonathan W Mink, Randal C Paniello, and Joel S Perlmutter


Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature.
Beth E Crowner, Diego Torres-Russotto, Alexandre R Carter, and Brad A Racette


Botulinum toxin effects on gasatrocnemius strength and plantar pressure in diabetics with peripheral neuropathy and forefoot ulceration.
Mary K Hastings, Michael J Mueller, David R Sinacore, Michael J Strube, Beth E Crowner, Jeffrey E Johnson, and Brad R Racette


Neuromythology of Manganism.
Kristin M Andruska and And Brad A Racette


Natural history of multiple system atrophy in the USA: a prospective cohort study.
Phillip A Low, Stephen G Reich, Joseph Jankovic, Clifford W Shults, Matthew B Stern, Peter Novak, Caroline M Tanner, Sid Gilman, Frederick J Marshall, Frederick Wooten, Brad Racette, Thomas Chelimsky, Wolfgang Singer, David M Sletten, Paola Sandroni, and Jay Mandrekar


Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
Kevin Michael Biglan, Ira Shoulson, Karl Kieburtz, David Oakes, Elise Kayson, M Aileen Shinaman, Hongwei Zhao, Megan Romer, Anne Young, Steven Hersch, Jack Penney, Karen Marder, Jane Paulsen, Kimberly Quaid, Eric Siemers, Caroline Tanner, William Mallonee, Greg Suter, Richard Dubinsky, Carolyn Gray, Martha Nance, Scott Bundlie, Dawn Radtke, Sandra Kostyk, Corrine Baic, James Caress, Francis Walker, Victoria Hunt, Christine O'Neill, Sylvain Chouinard, Stewart Factor, Timothy Greenamyre, Cathy Wood-Siverio, Jody Corey-Bloom, David Song, Guerry Peavy, Carol Moskowitz, Melissa Wesson, Ali Samii, Thomas Bird, Hillary Lipe, Karen Blindauer, Frederick Marshall, Carol Zimmerman, Jody Goldstein, Diana Rosas, Peter Novak, John Caviness, Charles Adler, Amy Duffy, Vicki Wheelock, Teresa Tempkin, David Richman, Lauren Seeberger, Roger Albin, Kelvin L Chou, Brad Racette, Joel S Perlmutter, Susan Perlman, Yvette Bordelon, Wayne Martin, Marguerite Wieler, Blair Leavitt, Lynn Raymond, Joji Decolongon, Lorne Clarke, Joseph Jankovic, Christine Hunter, Robert A Hauser, Juan Sanchez-Ramos, Sarah Furtado, Oksana Suchowersky, Mary Lou Klimek, Mark Guttman, Rustom Sethna, Andrew Feigin, Marie Cox, Barbara Shannon, Alan Percy, Leon Dure, Madaline Harrison, William Johnson, Donald Higgins, Eric Molho, Constance Nickerson, Sharon Evans, Douglas Hobson, Carlos Singer, Nestor Galvez-Jimenez, Kathleen Shannon, Cynthia Comella, Christopher Ross, Marie H Saint-Hilaire, Claudia Testa, Adam Rosenblatt, Penelope Hogarth, William Weiner, Peter Como, Rajeev Kumar, Candace Cotto, Julie Stout, Alicia Brocht, Arthur Watts, Shirley Eberly, Christine Weaver, Tatiana Foroud, James Gusella, Marcy MacDonald, Richard Myers, Stanley Fahn, and Clifford Shults


β2-adrenoreceptor medications and risk of Parkinson disease
Susan Searles Nielsen, Anat Gross, Alejandra Camacho-Soto, Allison W. Willis, and Brad A. Racette


Well Water and Parkinson's Disease in Medicare Beneficiaries: A Nationwide Case-Control Study
Maya R. Silver, Brad A. Racette, Umber Dube, Irene M. Faust, and Susan Searles Nielsen


Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression
Albert A. Davis, Kristin M. Andruska, Bruno A. Benitez, Brad A. Racette, Joel S. Perlmutter, and Carlos Cruchaga

*Updated as of 05/24/22.